156 related articles for article (PubMed ID: 10523601)
21. Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel.
Na'amnih W; Adler A; Miller-Roll T; Cohen D; Carmeli Y
Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1281-1288. PubMed ID: 29627951
[TBL] [Abstract][Full Text] [Related]
22. A rare case of Clostridium paraputrificum bacteremia in a 78-year-old Caucasian man diagnosed with an intestinal neoplasm.
Intra J; Milano A; Sarto C; Brambilla P
Anaerobe; 2020 Dec; 66():102292. PubMed ID: 33171286
[TBL] [Abstract][Full Text] [Related]
23. Vancomycin-resistant Clostridium innocuum bacteremia following oral vancomycin for Clostridium difficile infection.
Hung YP; Lin HJ; Wu CJ; Chen PL; Lee JC; Liu HC; Wu YH; Yeh FH; Tsai PJ; Ko WC
Anaerobe; 2014 Dec; 30():24-6. PubMed ID: 25102472
[TBL] [Abstract][Full Text] [Related]
24. Clostridium septicum and neutropenic enterocolitis.
Lancet; 1987 Sep; 2(8559):608. PubMed ID: 2887894
[No Abstract] [Full Text] [Related]
25. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.
Jones RN; Marshall SA
Diagn Microbiol Infect Dis; 1994 May; 19(1):33-8. PubMed ID: 7956010
[TBL] [Abstract][Full Text] [Related]
26. Cefepime.
Hardin TC; Jennings TS
Pharmacotherapy; 1994; 14(6):657-68. PubMed ID: 7885968
[TBL] [Abstract][Full Text] [Related]
27. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
[TBL] [Abstract][Full Text] [Related]
28. Lactobacillus species as emerging pathogens in neutropenic patients.
Fruchart C; Salah A; Gray C; Martin E; Stamatoullas A; Bonmarchand G; Lemeland JF; Tilly H
Eur J Clin Microbiol Infect Dis; 1997 Sep; 16(9):681-4. PubMed ID: 9352263
[TBL] [Abstract][Full Text] [Related]
29. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
[TBL] [Abstract][Full Text] [Related]
30. Antibiotic use in neonatal sepsis.
Yurdakök M
Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
[TBL] [Abstract][Full Text] [Related]
31. Antibiotic susceptibility of streptococci isolated from blood from neutropenic patients.
Piérard D; de Meyer A; Lauwers S
Pathol Biol (Paris); 1994 May; 42(5):471-4. PubMed ID: 7824316
[TBL] [Abstract][Full Text] [Related]
32. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Yee YC; Thornsberry C; Brown SD; Bouchillon SK; Marler JK; Rich T
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():13-9. PubMed ID: 8150756
[TBL] [Abstract][Full Text] [Related]
34. Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.
Montalar J; Segura A; Bosch C; Galan A; Juan O; Molins C; Giner V; Aparicio J
Med Oncol; 2002; 19(3):161-6. PubMed ID: 12482126
[TBL] [Abstract][Full Text] [Related]
35. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Barradell LB; Bryson HM
Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
[TBL] [Abstract][Full Text] [Related]
36. Clostridium innocuum is a significant vancomycin-resistant pathogen for extraintestinal clostridial infection.
Chia JH; Feng Y; Su LH; Wu TL; Chen CL; Liang YH; Chiu CH
Clin Microbiol Infect; 2017 Aug; 23(8):560-566. PubMed ID: 28254687
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample.
Pfaller MA; Marshall SA; Jones RN
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):273-6. PubMed ID: 9458985
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibility of Clostridium difficile from different sources.
Nakamura S; Nakashio S; Mikawa M; Yamakawa K; Okumura S; Nishida S
Microbiol Immunol; 1982; 26(1):25-30. PubMed ID: 7087801
[TBL] [Abstract][Full Text] [Related]
39. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
40. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
Johnson CC; Livornese L; Gold MJ; Pitsakis PG; Taylor S; Levison ME
J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
